Eli Lilly's tirzepatide is off FDA's shortage list
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Meanwhile, Eli Lilly is fighting off competition from copycat weight-loss drugs and other drug developers entering the lucrative field, and coming under increasing pressure from politicians ...
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback